Optimal management of giant cell arteritis and polymyalgia rheumatica

By R. Charlton. Therapeutics and Clinical Risk Management, 2012

873 citations recorded by the source corpus.

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are clinical diagnoses without “gold standard” serological or histological tests, excluding temporal artery biopsy for GCA. Further, other conditions may mimic GCA and PMR. Treatment with 10–20 mg of prednisolone daily is suggested for PMR or 40–60 mg daily for GCA when temporal arteritis is suspected. This ocular involvement of GCA should be treated as a medical emergency to prevent possible blindness and steroids should be commenced immediately. There are no absolute guidelines as to the dose or duration of administration; the therapeutics of treating this condition and the rate of reduction of prednisolone should be adjusted depending on the individual’s response and with consideration of the multiple risks of high-dose and long-term glucocorticoids. Optimal management may need to consider the role of low-dose aspirin in reducing complications. Clinicians should also be aware of studies that indicate an increased incidence of large-artery complications with GCA. This clinical area requires further research through future development of radiological imaging to aid the diagnosis and produce a clearer consensus relating to diagnosis and treatment.

Subfields: Genetics, Pulmonary and Respiratory Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/c9482353fe0966b139ed55f40dd5178903478cc7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

Citations in the corpus

Are precision agriculture tools and methods relevant at the whole-vineyard scale? (2013, background): “…has highlighted the ability of high resolution data to match within field variability at this scale (Acevedo-Opazo et al., 2008a, Acevedo-Opazo et al., 2008b), and the potential benefits of its management according to the obtained zoning (Bramley et al., 2004, Taylor, 2004, Arnó et al., 2009).”